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ABSTRACT 21 
Background: CD24highCD38high transitional B cells represent cells at a key stage in their 22 
developmental pathway. During this stage, B cells undergo peripheral tolerance and functional 23 
maturation. In addition, these B cells have been widely ascribed regulatory functions and 24 
involvement in the control of chronic inflammatory diseases. However, the phenotypic and 25 
functional overlap between these cells and regulatory B cells remain controversial. 26 
Objective and Methods: In this study, we use multi-color flow cytometry in 27 
combination with bioinformatics and functional studies to show that CD24highCD38high B cells 28 
can be distinguished into multiple subsets with different regulatory functions. 29 
Results: The study reveals for the first time that human transitional B cells encompass 30 
not only transitional type 1 (T1) and T2 B cells, as previously suggested, but also distinct anergic 31 
T3 B cells as well as IL-10-producing CD27+ transitional B cells. Interestingly, the latter two 32 
subsets differentially regulate CD4+ T cell proliferation and polarization towards Th1 effector 33 
cells. Additional analyses reveal that the percentage of T3 B cells is reduced while the frequency 34 
of CD27+ transitional B cells is increased in patients with autoimmune diseases compared with 35 
matched healthy individuals. 36 
Conclusion: This study provides evidence for the existence of different transitional B cell 37 
subsets each displaying unique phenotypic and regulatory functional profiles. Furthermore, the 38 
study indicates that altered distribution of transitional B cells subsets highlights different 39 
regulatory defects in different autoimmune diseases. 40 
41 
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Key messages: Our study reveals that different human transitional B cell subsets display 42 
different regulatory functions and that the frequency of such subsets is differentially altered in 43 
different autoimmune diseases.  44 
Capsule summary: Recent studies of patients with autoimmune and inflammatory diseases 45 
indicate that B cells can prevent the development of adverse immune responses. This study 46 
documents the phenotype of human regulatory B cells and identifies potential cellular 47 
biomarkers that distinguish defects in immune regulation in patients with different autoimmune 48 
diseases.  49 
Key words: Transitional B-cells; Immune regulation; chronic inflammatory diseases; 50 
Autoimmunity 51 
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Abbreviations used: 53 
Flow clustering without K (FLOCK) 54 
Healthy controls (HCs) 55 
Krome orange (KO) 56 
Mean fluorescence intensity (MFI) 57 
Mononuclear cells (MNCs) 58 
Pacific blue (PB) 59 
PE-linked to cyanin 5 (PC5) 60 
Population (pop) 61 
Primary Sjögren’s syndrome (pSS) 62 
Rheumatoid arthritis (RA) 63 
Human immunodeficiency virus HIV 64 
Chronic antibody mediated rejection cABMR 65 
Standard error of the mean (SEM) 66 
Systemic lupus erythematosus (SLE) 67 
Type 1 (T1) 68 
Type 2 (T2) 69 
Type 3 (T3) 70 
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INTRODUCTION 71 
Transitional B cells represent a central developmental stage in B cell maturation 72 
linking generation in the bone marrow with differentiation in the periphery.1 The 73 
classification of murine transitional B cells into distinct type 1 (T1) and T2 subsets was 74 
subsequently reported, based on the expression of CD23, CD21 and the developmental 75 
marker CD24.2 Studies of human B cells confirmed and extended the identification of 76 
transitional B cells in mice.3,4 The early studies suggested that transitional human B cells can 77 
be subdivided into two major subsets: immature-T1 cells identified as 78 
CD24highCD38highCD19+CD10highCD21lowIgMhighIgDlowCD27-CD5+ cells and intermediate 79 
transitional cells (T2) that are CD24highCD38highCD19+CD10+CD21+IgMhigh IgD+CD27-80 
CD5low cells.  81 
The almost concurrent discovery of regulatory B cells (Bregs) drew interests towards 82 
potential links with transitional B cells due to phenotypic and functional similarities. Bregs 83 
were first reported to be IL-10-producing B cells in mice and termed B10 cells.5 Although 84 
almost all human B cells have the capacity to produce IL-10, the available evidence indicates 85 
that the "most efficient" IL-10 producing B cells are Bregs that are similar to 86 
CD24highCD38high transitional B cells.6-9 Furthermore, associations between CD24highCD38high 87 
B cells and immune regulation were noted in the favorable clinical outcome of patients with 88 
chronic inflammatory and autoimmune diseases. For example, long-term remission of patients 89 
with systemic lupus erythematosus (SLE) treated with B cell depleting biologic agents 90 
positively correlated with early reconstitution of transitional B cells after treatment.10 Specific 91 
allergen immunotherapy drives suppression of IgE and promotion of IgG4 production by 92 
regulatory B cells.11 These observations led investigators to draw parallels between 93 
CD24highCD38high transitional B cells and Breg cells.7,12-17 This, in turn, led to numerous 94 
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studies and the emergence of differing theories about the relationship between transitional and 95 
“real” Breg cells.  96 
To increase understanding of CD24highCD38high transitional B cells and potential 97 
overlaps with Breg cells in human, we developed a 10-color flow cytometry protocol for their 98 
phenotypic and functional characterization. The study reveals that CD24highCD38high B cells 99 
incorporate phenotypically-distinct B cell subsets, each with distinct in vitro regulatory 100 
functions. Furthermore, the study reveals abnormal distribution of transitional B cell subsets 101 
in different autoimmune diseases, revealing new insights into Breg development and 102 
phenotype and aspects of defective immune regulation in different chronic inflammatory 103 
diseases. 104 
105 
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METHODS  106 
Detailed procedures and standard methods used in the study, such as cell enrichment, 107 
flow cytometry, apoptosis, ELISA, ELISPOT, Ca++ flux and cell culture are described in the 108 
Supplemental Materials. 109 
 Patients and controls  110 
All patients and healthy controls (HCs) gave informed consent and the Ethics 111 
Committee at Brest University Medical School Hospital approved the study to be conducted 112 
in accordance with the Declaration of the Helsinki Principles. Table 1 summarizes the 113 
characteristics of patient groups included in the study. 114 
 Flow cytometry and cell sorting 115 
All antibodies (Abs) were purchased from Beckman Coulter unless otherwise 116 
specified. All Abs used to make up the 10-color panel are listed in Table E1. Transitional B 117 
cell subsets and CD4+ T cells were sorted with MoFlow XDP (Dako-Beckman Coulter). The 118 
purity of the sorted B cell subsets and T cells was greater than 98%. 119 
 Cell culture and proliferation assays 120 
Sorted transitional B cells and CD4+ T cells were co-cultured for 4 days in RPMI -121 
1640 complete medium as described.18 For proliferation assays, sorted CD4+ T cells were 122 
labeled with CellTraceTM Violet reagent (Molecular Probes) before the co-culture. T cell 123 
proliferation was evaluated by flow cytometry using cell proliferation index in the FlowJo 124 
software (FlowJo, LLC). 125 
SIMON ET AL     8 
 Bioinformatic analyses and softwares 126 
Bioinformatic analyses were performed with Flow Clustering without K online 127 
software (FLOCK). Files for each subject were uploaded to ImmPort (ImmPort, NIH website 128 
www.immport.org) and analyzed using FLOCK 1.0 to identify centroids for representative 129 
clusters. Markers listed in Table. E1 were used. CytoSpanning tree Progression of Density 130 
normalized Events (SPADE) analysis was carried out using Cytobank Inc. platform as 131 
described.19  132 
 Statistics 133 
All data are expressed as the mean ± standard error of the mean (SEM). Statistical 134 
analyses were performed using GraphPad Prism version 5.03 (GraphPad software). Non 135 
parametric Mann-Whitney U-test, or Wilcoxon t-test for paired observations were used and 136 
data were considered significant when P<0.05.  137 
138 
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RESULTS 139 
 The frequency of CD24highCD38high B cells is variable in different diseases  140 
High level co-expression of CD24 and CD38 identifies circulating transitional human 141 
B cells and is often used by investigators for quantifying Breg cells in peripheral blood. We 142 
have observed that the frequency of CD24highCD38high B cells in healthy controls (HCs) is 143 
12.9±0.8% of total blood B cells but this frequency varies in different clinical settings (Fig 1, 144 
A and Table 1). The frequency of CD24highCD38high B cells in patients with primary Sjögren’s 145 
syndrome (pSS) and SLE was significantly higher than in the HCs (15.5±1.2% and 146 
17.9±1.8%, P=0.008, P=0.0037, respectively; Fig 1, B, left panel). This trend concurred with 147 
a similar increase in the absolute number of the transitional B cells (Fig 1, B, right panel). In 148 
contrast, patients with chronic antibody-mediated kidney rejection (cABMR) showed a 149 
significant decrease in the frequency of CD24highCD38high B cells compared with the HCs 150 
(2.4±0.4%, P<10-3).18 Interestingly, during the active course of HIV infection, patients 151 
manifested a dramatic decrease in transitional B cells (5.3±1.1% vs HCs, P<10-3). These 152 
observations suggest that it is difficult to universally associate decreases/increases in the 153 
frequency/number of CD24high CD38high B cells with pathophysiological mechanisms.  154 
 Detailed characterization of CD19+ CD24highCD38high B cell subsets 155 
In order to categorize CD24highCD38high populations in B cells, we carried out a 10-156 
color flow cytometry analysis using the FLOCK (Flow clustering without K) software 157 
system.20 First, we identified pre-gated transitional B cells as defined by high expression 158 
levels of CD24 and CD38 in 2D plots within CD19+ B cells (Fig 2, A). Next, we ran the 159 
FLOCK software on compiled flow cytometry data from 15 independent experiments using 160 
isolated B cells from the HCs. This enabled us to identify eight B cell clusters within the 161 
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CD24highCD38high parent gate that partially overlapped in several Ab panels (Fig 2, A and Fig 162 
E1). Clusters 2, 3 and 5 were consistently found to be the three most abundant B cell clusters 163 
in CD24highCD38high transitional B cells (cluster 2: 28.6±1.7%; cluster 3: 15.1±1.5% and 164 
cluster 5: 25.0±2.0%). In order to further characterize these subsets, we studied the expression 165 
level of additional different markers in each cluster. We observed that among the ten chosen 166 
markers, CD27, IgM and IgD were the best in differentiating B cell subsets within the 8 167 
clusters based on their mean fluorescence intensity (MFI) (Fig 2, B and Fig E2, A). Cluster 6 168 
displayed the highest MFI for CD27 expression (163946.7) compared with the other clusters 169 
(P<10-3 vs cluster 1 and 3; others were negative for CD27). The MFI for IgM expression was 170 
higher in cluster 3 than in cluster 1 or 2 (P<10-3). Cluster 2 had a significantly reduced level 171 
of IgD and IgM expression compared with the other clusters with none of the clusters 172 
expressing IgG or IgA (Fig 2, C and Fig E2, B). When the data were compiled together, 173 
clusters 1, 4, 5, 7 and 8 expressed significantly higher IgM MFI than cluster 2 and less IgD 174 
than cluster 3 and 6 (P<10-3 and P=0.037, respectively) (Fig 2, C). Analysis of other markers 175 
confirmed the noted distinctiveness of clusters 2 and 3 (Fig E2, A). We further observed that 176 
CD10 expression was higher in cluster 3 than in the other clusters, while cluster 2 had an 177 
intermediate level of CD21 expression. Consequently, we congregated the 8 clusters into four 178 
different patterns based on CD27, IgM and IgD expression. Cluster 6 (CD27+) was renamed 179 
population (pop) A. Cluster 3 (IgDlowIgMhigh) was branded pop B. Cluster 2 (IgMlowIgD+) was 180 
named pop C. Finally, we grouped clusters 1, 4, 5, 7 and 8 that expressed similar levels of 181 
IgM and IgD into pop D (Fig 2, C). Cross sample comparison of these four populations was 182 
highly consistent between different blood donors (Fig 2, D). Populations C and D represented 183 
the majority of CD24highCD38high B cells (55.7±1.3% and 30.1±1.5, respectively) whereas pop 184 
B represented 7.3±0.8% and pop A 6.0±0.7% of all CD24high CD38high B cells. 185 
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 Phenotypic characterization of transitional B cell subsets identified by FLOCK 186 
We next carried out detailed phenotypic analysis of these four defined populations 187 
using markers commonly ascribed to B cell-differentiation, survival or activation (Fig 3). 188 
B cell-differentiation and activation markers 189 
These analyses revealed that each cluster showed a unique B cell profile of 190 
differentiation (Fig 3, A) and activation (Fig 3, B). Pop A expressed CD27 and high levels of 191 
all of the other differentiation markers with the exception of CD23. This population, thus, 192 
expressed high levels of CD80, CD86, CD40, CD25 and TLR-9, depicting a high activation 193 
status.  Pop B expressed lower levels of CD21, CD22, CD23, CD44, and CD62L than the 194 
other 3 populations but had high levels of CD10 and CD32 (Fig 3, A). The results also 195 
revealed lower basal expression levels of HLA-DR, CD80, CD86 and CD25 in pop C 196 
compared with pop D (Fig 3, B). This data suggests that pop C may be in a resting-state.  197 
Mitotracker expression 198 
The activity of the ATP-binding cassette transporter ABCB1 has been described as a 199 
functional characteristic that distinguishes transitional from mature naive B cells.21 The level 200 
of MTG-Green MFI gradually decreased from pop B to pop D and C implying a 201 
developmental pathway through these subsets (Fig 3, C). Interestingly, pop A did not extrude 202 
the probe at all, supporting the likelihood that this subset has a memory-like phenotype.  203 
By compiling these descriptive data, the results provide evidence that pop B presents a 204 
pattern of differentiation close to immature B cells as described for T1 B cells (Fig 3, D). Pop 205 
D, in contrast, showed a progressive pattern of upregulating maturity markers, IgD, CD21, 206 
CD44 and CD62L. The pattern observed in this population is in agreement with the 207 
previously defined T2 subset of B cells. In contrast, pop C displayed an intermediate profile 208 
of these markers consistent with been in a resting state described for T3 B cells.22 Finally, pop 209 
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A represents an atypically-activated B cell with a memory-like phenotype, renamed CD27+ 210 
transitional B cells (Fig 3, D). 211 
 Functional characteristics of T1, T2, T3 and CD27+ transitional B cell subsets 212 
To corroborate the phenotypic distinction between the transitional B cell subsets, 213 
functional characteristics of the subsets were investigated including analyzing survival and 214 
responses to BCR engagement. 215 
Survival capacity 216 
Reduced survival has been reported to be a functional characteristic of transitional B 217 
cells.3,23 To compare and contrast this ability within the different subsets, we first analyzed 218 
viability of the different CD24highCD38high B cell subsets in the absence of exogenous stimuli 219 
(Fig 4, A). The analysis revealed no significant differences between the subsets for early 220 
spontaneous apoptosis. Interestingly, CD27+ transitional B cells showed a high necrotic rate 221 
in culture (Draq7+ and Annexin V+ cells). We next studied whether BCR engagement will 222 
modify survival of the transitional B cell subsets. Because staining B cells with FITC-223 
conjugated anti-IgM Ab interferes with their response to BCR engagement, we developed an 224 
alternative gating strategy using CD27, IgD and CD32 (Fig 4, B). As depicted in the Figure, 225 
the newly-set gate for T1 (CD32+IgDlow), T2 (CD32highIgDhigh) and T3 (CD32lowIgDlow) B 226 
cells perfectly matched our earlier phenotypic description of these subsets. BCR engagement 227 
increased apoptosis in the T1 B cell subset and did not increase survival of the other subsets 228 
(Fig 4, A). 229 
Hyporesponsiveness of T3 B cells to BCR engagement 230 
Low density surface IgM is a hallmark of anergic B cells in mice and humans.24 Such 231 
anergic B cells have been shown to be over-represented in transitional B cells.25 To determine 232 
the tolerance status of the B cell subsets identified in the current study, we next determined 233 
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the functional response of the CD24highCD38high B cell subsets to BCR engagement. The 234 
ability of each subset to mobilize Ca2+ after BCR engagement was assessed by flow 235 
cytometry.26 BCR engagement induced similar increases in [Ca2+] influx in CD27+ and T2 B 236 
cells (Fig 5 A). T3 B cells were unresponsive to BCR engagement as indicated by a failure to 237 
mobilize Ca2+ upon BCR engagement consistent with low levels of BCR expression.24 To 238 
confirm this observation, we next analyzed the release of PIP3 and phosphorylation of 239 
PLC2.27 According to their inability to mobilize Ca2+, T3 B cells did not show an increase in 240 
PIP3 release (Fig 5, B, left panel) or increased PLC2 phosphorylation following BCR 241 
engagement (Fig 5, B, right panel). These findings indicate that the T3 subset of transitional B 242 
cells is refractory to BCR engagement consistent with a functional silencing similar to 243 
immunological anergy. 244 
T1 and CD27+ transitional B cells provide innate humoral immunity 245 
Transitional B cells are capable of contributing to innate humoral immunity by 246 
differentiating to polyreactive IgM Ab-producing cells.28 We, therefore, assessed whether 247 
differences existed between the transitional B cell subsets in their ability to produce natural 248 
IgM Abs. CD24highCD38high B cell subsets were sorted by flow cytometry (purity indicated in 249 
Fig E3, A) and incubated for 4 days with CpG (to mimic T cell-independent stimulation). B 250 
cell differentiation was then analyzed by flow cytometry. The results revealed two 251 
differentiated populations: CD27highCD38high plasmablasts and CD27+CD38- memory B cells 252 
(Fig 5, C).29 After 4 days of culture, CD27+ transitional B cells differentiated significantly 253 
more to memory B cells (15.2±1.2%) than T1 B cells did (2.3±0.4%). A very small number of 254 
T2 B cells acquired a memory phenotype (0.66±0.1%) while almost none became 255 
plasmablasts. T3 B cells, consistent with their functional silencing, did not differentiate upon 256 
CpG stimulation.  257 
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We next analyzed the ability of the sorted transitional B cell subsets to secrete natural 258 
IgM using ELISPOT (Fig 5, C, lower panel). Interestingly, T1 and CD27+ transitional B cells 259 
showed a high capacity to differentiate into IgM secreting cells. None of the populations 260 
switched Abs from IgM to IgG or IgA (data not shown). 261 
All in all, the results demonstrate that transitional CD27+ and T1 B cells are highly 262 
efficient producers of IgM Abs typical of innate immune responses consistent with an "innate 263 
memory" cell phenotype. 264 
 The regulatory functions of transitional B cell subsets 265 
IL-10 production 266 
Previous studies have revealed that B cell subsets producing IL-10 are consistently 267 
found within CD24highCD38high B cells and CD24highCD27+ cells.30 To further determine 268 
functional characteristics of the transitional B cell subsets, we next studied spontaneous IL-10 269 
production in vitro without stimulation (Fig 6). Using a successive gating strategy (Fig 6, A) 270 
we observed that IL-10-producing B cells were mainly enriched in the T2 and CD27+ B cell 271 
subsets (35.1±6.6% and 50.7±7.4% of IL-10+ B cells, respectively) (Fig 6, B, left panel). 272 
Interestingly, the MFI for intracellular IL-10 expression was significantly higher in CD27+ 273 
transitional B cells than in the other transitional subsets (P<10-3, Fig 6, B middle panel). 274 
When the analysis was repeated but with B cells stimulated through the TLR9 for 24 hours 275 
with CpG ODN there was a dramatic increase in IL-10+ B cells within the T2 and T3 subsets 276 
(Fig 6, C, left panel). Activation of the cells through TLR9 with CpG enhanced intracellular 277 
IL-10 expression (IL-10 MFI) in the pre-existing IL10+CD27+ transitional B cells (Fig 6, C, 278 
right panel and Fig E4). Finally, to objectively present the data on spontaneous IL-10 279 
production by the different B cell subsets, we used Spanning-tree Progression Analysis of 280 
density-normalized Events (SPADE) software which maps cells in a hierarchical tree19 (Fig 6, 281 
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D). To interpret the SPADE tree, we derived annotations according to the differential pattern 282 
of expression of each marker previously chosen to differentiate the various transitional B cell 283 
subsets: CD24, CD38, IgM, IgD, CD27, CD32 and CD19. The data confirmed that the CD27+ 284 
and T2 transitional B cell subsets were the most inherently competent cells in producing IL-285 
10. Interestingly, the SPADE analysis revealed that lower levels of IL-10 could also be 286 
produced by other B cell subsets. 287 
Transitional CD27+B cells inhibit TNF and IFNγ production by T cells 288 
The available evidence indicates that transitional human B cells were the most 289 
efficient subset of Breg cells in inhibiting TNF and IFNγ production by T cells.7,18 To 290 
determine which of the transitional B cells characterized in this study best manifests the 291 
ability to regulate cytokine production by T cells, we used a specially-adapted in vitro model 292 
system.31 The transitional B cell subsets were FACS-sorted (purity >98% as depicted in Fig 293 
E3, A) and co-cultured with anti-CD3 and anti-CD28 Abs-activated CD4+ T cells (purity 294 
>99% shown in Fig E3, B). All transitional B cell subsets were able to reduce TNFα 295 
production by CD4+ T cells but the CD27+ B cell subset was the most efficient (P=0.015 vs 296 
T1 B cells; P=0.015 vs T2 B cells; P=0.0078 vs T3 B cells) (Fig 7, A). Interestingly, CD27+ 297 
transitional B cells were the only subset within transitional B cells capable of significantly 298 
suppressing both TNF and IFN production by CD4+ T cells (P=0.0078).  299 
Anergic-like T3 B cells regulate T cell proliferation  300 
In the next set of experiments, proliferation of the sorted CD4+ T cells was studied by 301 
flow cytometry at day 4 in the presence or absence of sorted transitional B cell subsets (Fig 7, 302 
B). T1 and CD27+ transitional B cells were unable to suppress T cell proliferation. In contrast 303 
T2 and T3 exhibited a significant ability to reduce CD4+ T cell proliferation. Interestingly, the 304 
T3 B cell subset showed the highest reproducibility in the ability to reduce T cell proliferation 305 
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among different donors when compared with T2 B cells suggesting that the latter might be 306 
composed of different functional subsets. 307 
These observations demonstrate that transitional B cell subsets have differential 308 
abilities to regulate T cell responses.  309 
 Altered distribution of transitional B cell subsets in patients with different 310 
autoimmune diseases 311 
Results presented in Fig 1 provided evidence that the percentage of CD24highCD38high 312 
B cells was significantly higher in patients with pSS and SLE compared with HCs. Based on 313 
these observations we investigated the distribution of each of the transitional B cell subsets 314 
characterized in the study in patients with these autoimmune diseases. For this purpose, we 315 
performed a FLOCK cross sample comparison of 10-color flow-cytometry data on enriched B 316 
cells from 10 HCs, 11 patients with pSS and 10 patients with SLE (Figs 7, C and D). The 317 
results showed that the frequency of CD27+ transitional B cells was significantly increased in 318 
patients with pSS and SLE compared with the HCs (P=0.03 and P=0.0011, respectively; Fig 319 
7, C). Interestingly, the frequency of T3 B cells was decreased in the patients compared with 320 
the HCs (P=0.006 in pSS patients and P=0.028 in SLE patients; Fig 7, D) whereas T1 and T2 321 
B cells were similar. These findings suggest that T3 and CD27+ transitional B cells may have 322 
been influenced by a breach in peripheral-tolerance in these patients. 323 
324 
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DISCUSSION 325 
Phenotypic and functional features of transitional B cells have been extensively 326 
studied in mice leading to a qualified consensus that at least three major subsets of these cells 327 
exist.2,22,25 In humans, however, the biology of transitional B cells remains controversial. T1 328 
and T2 subsets have consistently been identified within CD24highCD38high B cells.32 In 329 
contrast, T3 B cells have been suggested to be part of the mature B cell pool.4,21 In the current 330 
study, we identified the T1 and T2 subsets by their differential capacity to survive or undergo 331 
apoptosis with BCR engagement. In vitro and in vivo studies revealed that whilst T1 B cells 332 
underwent apoptosis upon BCR engagement, T2 B cells proliferated and were resistant to 333 
apoptosis.33,34 However, our study provides new evidence for the existence of two additional 334 
transitional B cell subsets with distinct phenotypic and functional properties. One subset, T3 335 
B cells, expressed low levels of IgM, IgD and CD10 and displayed functional status similar to 336 
anergic cells. The second subset which includes CD27+ transitional B cells have not been 337 
described before as transitional B cells because CD27 expression is generally considered a 338 
memory B cell marker. Nevertheless, we have demonstrated that 6.0±0.7% of 339 
CD24highCD38high B cells express CD27+. Furthermore, these cells responded rapidly to T 340 
cell-independent stimuli and secreted natural IgM Abs consistent with innate-like B cells.35,36 341 
CD27+ transitional B cells may represent cells at a developmental stage in an alternative 342 
differentiation pathway that responds to TLR ligands. In mice, recent studies indicate that 343 
some transitional B cells have the potential to differentiate into plasmablasts and natural 344 
memory B cells.37,38 The identification of multiple human transitional B cell subsets in the 345 
current study could, therefore, provide important new insights indicating the existence of 346 
multiple developmental programs through which human migrant B cells undergo tolerance 347 
and maturation. Based on the findings made in the study, we developed a new paradigm (Fig 348 
E5) that includes a novel developmental pathway for transitional B cell maturation in humans.  349 
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As a corollary to our hypothesis, we demonstrate that transitional B cell subsets 350 
identified within the CD24highCD38high parent flow cytometry gate display differential 351 
regulatory abilities. Thus, we reveal that CD27+ transitional B cells are specialized in 352 
suppressing the production of pro-inflammatory cytokines. This subset of transitional B cells 353 
has the capacity to produce high levels of IL-10 (Fig 6). Although the ability to produce IL-10 354 
is often used as a marker of human Bregs, we show that this is a property that is not restricted 355 
to a specific B cell subset. Indeed, our flow cytometry and bioinformatics analyses revealed 356 
that IL-10 can be produced by transitional B-cells subsets, by CD27+CD24high cells30 and by 357 
IgM+IgD- memory B cells39 (Fig 6). Furthermore, our data are consistent with studies of B 358 
cells in mice showing that B1030,40,41 progenitor and effector cells may coexist in human 359 
transitional B cells (Fig 6 and Fig E4). Interestingly, T3 anergic-like B cells possessed the 360 
best and most consistent ability to control T cell proliferation. The inconsistent suppressive 361 
ability of T2 B cells suggested that this subset may be composed of more than one functional 362 
subset. Indeed, the Flock analysis (Fig 2 and Fig E1) indicated that T2 B cells encompassed 5 363 
different clusters of B cells. In this respect, several previous reports have suggested that T2 B 364 
cells are heterogeneous and include some follicular and marginal zone B cells.42,43 The precise 365 
mechanism by which anergic B cells exhibit potent regulatory activities remains to be fully 366 
defined. In this respect, it has been suggested that B cells can be tolerogenic to T cells when 367 
presenting a limited number of antigen peptides/MHC complexes to T cells.44 This 368 
characteristic was described for anergic B cells.45 Additionally, the lack of costimulatory 369 
molecules (Fig 3) on the anergic-like B cells may induce anergy in the corresponding, 370 
antigen-specific, T cells.46 Relevant to this observation, a recent study demonstrated that 371 
Ars/A1 anergic B cells are potent suppressors of humoral immunity in an IL-10 independent 372 
manner.47 373 
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These observations cast new lights on existing but rather conflicting data on the 374 
phenotype of Breg cells by underlying the differential ability of different B cell subsets to 375 
regulate distinct T cell responses. Thus, our study demonstrates for the first time that immune 376 
regulation by B cells is not confined to a "particular" B cell subset and also not in a 377 
functionally restricted manner. Instead, the data show that different B cell subsets can have 378 
different regulatory properties determined not only by their own developmental pathway and 379 
activation status but also by how the target cell is influenced by its microenvironment. In this 380 
regard, a recent report suggested a developmental link between human transitional B-cells and 381 
IL-10-producing plasmablasts.38 382 
Using FLOCK cross-sample comparison analyses, the last part of our study revealed 383 
that patients with autoimmune diseases display abnormal distribution of transitional B cell 384 
subsets. Interestingly, CD27+ transitional B cells were over-represented in patients with SLE 385 
and pSS whereas the frequency of anergic-like T3 B cells was decreased. An increase in 386 
transitional B cells in patients with SLE patients has been described before but this did not 387 
correlate with disease activity.3 Reduction in the frequency of T3 B cells is consistent with the 388 
persistence of increased numbers of autoreactive mature B cells in such patients (25-31% in 389 
SLE patients vs 4-3% in HCs) as previously observed.48 Furthermore, B cells from patients 390 
with SLE have been reported to be defective in their ability to suppress T cell 391 
proliferation.49,50 However, further investigation of transitional B cell subsets would be 392 
required to accurately identify defective immune regulatory pathways in different diseases. 393 
Nevertheless, the study provides preliminary evidence that transitional B cells are not a 394 
homogeneous regulatory B cell population but rather represent a complex mixture of subsets 395 
from which different Bregs emerge.51 The findings, thus, provide a new approach to define 396 
cellular biomarkers that identify specific defects in immune regulation in different diseases.  397 
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FIGURES AND LEGENDS 543 
FIG. 1. Comparison of CD24highCD38high transitional B cell subsets in 544 
patients and healthy controls. Blood from 33 HCs (■), 17 patients 545 
with pSS (○), 16 patients with SLE (●), 15 patients with RA (), 17 546 
patients with cABMR (▲) and 26 patients infected with HIV (◊) were 547 
analyzed by flow cytometry. A, Representative dot plots of CD24 and 548 
CD38 expression and percentage of CD24highCD38high cells in CD19+ 549 
B cells. B, Percentages (left panel) and absolute numbers (right panel) 550 
of CD19+ CD24highCD38high B cells in each group.*P<0.05, **P<0.01, 551 
***P<0.001. 552 
FIG. 2. Identification and phenotypic definition of transitional B cell 553 
subsets. B cells from 15 HCs were labeled with 10 Abs with 554 
specificities listed in Table E1. A, Eight clusters of transitional B cells 555 
were identified using FLOCK analysis. Representative dot plots of 556 
IgM/IgD and CD21/CD32 are shown in the left panel. The percentage 557 
of each cluster is depicted in the right panel as individuals values in 15 558 
HCs. B, CD27 (left), IgM (middle) and IgD (right) MFI expression on 559 
each cluster ***P<0.001. C, The grouping strategy for classifying cell 560 
clusters is presented for CD19/CD27 and IgM/IgD expression (two 561 
left panels) and their Mean±SEM of MFI (the two right panels). D, A 562 
supervised-FLOCK analysis according to the previous grouping 563 
strategy and percentages of defined pop A, B, C and D. 564 
FIG. 3. Broad phenotype of transitional CD24highCD38high B cell subsets. 565 
Representative histograms of the surface markers are indicated for 566 
each gated population: CD19+ B cells (black), CD19+ 567 
CD24highCD38high cells (grey), pop A (green), pop B (red), pop C 568 
(blue) and pop D (yellow). A, Expression of the differentiation 569 
markers B, Expression of co-stimulatory and activation markers. C, 570 
ABCB1 transporter activity. Mature naive B cells were identified as 571 
CD19+IgD+CD27-. D, A summary table indicating subset and 572 
population classification principles of transitional B cells and 573 
expression levels of the different markers. 574 
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FIG. 4. BCR engagement induces apoptosis in T1 B cells while CD27+ 575 
transitional B cells are prone to die in culture by necrosis. A, 576 
Percentages of apoptotic (Annexin V+ Draq7-) and necrotic cells 577 
(Annexin V+ Draq7+) are shown with and without BCR engagement 578 
for 8 hours (n=4), *P<0.05. B, Density of IgD and CD32 expression 579 
distinguishes T1 (IgDlow CD32+), T2 (IgD+CD32+) and T3 (IgDlow 580 
CD32low) in CD27- transitional B cells as does expression levels of 581 
IgD and IgM. 582 
FIG. 5. Transitional B cell subsets respond differently to BCR and Toll-583 
like receptor 9 (TLR9) engagements. A, Ca2+ flux after BCR 584 
engagement in different B cell subsets analyzed by flow cytometry. B, 585 
Intracellular staining for the level of PIP3 (left panel) and 586 
phosphorylated PLCγ2 (right panel) following BCR engagement 587 
(n=6) *P<0.05. C, In vitro plasmablast differentiation and total IgM 588 
secretion. Numbers under each of the developed membranes depict the 589 
number of IgM-secreting B cells. (n=3)  590 
FIG. 6. CD27+CD24highCD38high B cells are the most efficient spontaneous 591 
IL-10-producing transitional cells. A, The gating strategy used to 592 
evaluate IL-10 secretion by transitional B cell subsets. B, Percentages 593 
of T1, T2, T3 and CD27+ transitional B cells in IL-10+ cells and IL10- 594 
cells. The middle panel depicts MFI for intracellular IL-10 in each 595 
transitional B cell subset within IL-10 positive cells (n=4) *P<0.05, 596 
**P<0.01. C, Comparison of Mean±SEM of each transitional B cell 597 
subsets (and IL-10 MFI) in IL-10 positive CD24highCD28high B cells 598 
following 24 hours of stimulation with CpG (n=4) *P<0.05, 599 
**P<0.01. D, SPADE analysis of IL-10 density-based expression in 600 
all non stimulated B cell subsets.  601 
FIG. 7. CD27+ transitional B cells inhibit TNF and IFN production by 602 
cultured T cells, whereas T3 B cells limit CD4+ T cell proliferation 603 
and are differentially represented in patients with different 604 
autoimmune diseases. A, Sorted CD4+ T cells were cultured with 605 
each sorted transitional B cell subset for during 4 days. TNFα and 606 
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IFNγ levels were measured in supernatants from the cultured cells 607 
using ELISA (n=7). B, Representative histogram of CD4+ 608 
proliferating T cells cultured with or without sorted transitional B cell 609 
subsets (right panel). MeanSEM of proliferation index of sorted 610 
CD4+ T cells in the presence or absence of transitional B cell subsets 611 
(n=10, left panel). C, Percentages of T1 and CD27+ transitional B cell 612 
subsets within CD24highCD38high in HCs (■, n=9), patients with pSS 613 
(○, n=11) and SLE (●, n=10), after FLOCK cross-sample comparison. 614 
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Table 1. Characteristics of patients included in the study. 645 




pSS (n=17*) 56 (29-77) 17/0 CTC=3 ; PLQ=4 
SLE (n=16**) 41.5 (25-76) 14/2 CTC=4 ; PLQ=11, MPA=1 ; MTX=3 ; 
Thal.=2 
RA (n=15) 51 (29-80) 8/7 CTC=12 ; PLQ=2 ; MTX=10 ; RTX=3 ; 
anti-IL-6=1 ; anti-TNFα=7 
cABMR (n=17) 54.5 (27-73) 3/14 CTC=15/17 ; MPA=17/17 ; 
mTORi=2/17 
HIV (n=26) 50 (37-62) 8/16 Not informed 
Abbreviations: RA= Rheumatoid arthritis; cABMR= Chronic antibody-mediated kidney graft 646 
rejection; HIV= Human immunodeficiency virus; SLE= Systemic lupus erythematosus and 647 
pSS= Primary Sjögren’s syndrome. CTC= corticosteroids; PLQ= Plaquenil; MPA= 648 
Mycophenolic acid; MTX= Methotrexate; Thal.= Thalidomide; RXT= Rituximab; mTORi= 649 
Mammalian target of rapamycin inhibitor receptor; TNFα= Tumor Necrosis Factor alpha. *11 650 
patients with pSS and **10 with SLE were considered for the FLOCK cross sample 651 
comparison (Fig 7). 652 
 653 
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Table E1 List of fluorochrome-labelled antibodies used for the 10-color flow cytometry 655 
analysis. 656 
Specificity Clone Fluorochrome Functions 
CD19 J3-119 APC-AF700 Lineage 
CD21 BL-13 PB 
Signal transduction 
CD32 2E1 KO 
CD10 ALB1 PE B cell growth 
IgD IA6-2 APC 
Humoral response 
IgM SAD4 FITC 
CD27 1A4CD27 PE-Cy7 Memory 
CD38 LS198-4-3 PE-Cy5.5 Proliferation 
CD24 ALB9 APC-AF750 Proliferation 
CD5 BL1a ECD Signal transduction, Activation 
Abbreviations: AF: Alexa fluor; APC: Allophycocyanin; Cy: Cyanine; ECD: PE-Texas Red; 657 
FITC: Fluorescein isothiocyanate; PB: Pacific blue; PE: Phycoerythrin; KO: Krome orange. 658 
 659 
